Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
Prescrire Int
; 17(95): 109, 2008 Jun.
Article
em En
| MEDLINE
| ID: mdl-18630351
ABSTRACT
Weekly infusions of idursulfase have no tangible benefit in boys with type II mucopolysaccharidosis who already have respiratory involvement, while hypersensitivity reactions are frequent and sometimes serious. Idursulfase should only be given to infants if they are enrolled in clinical trials.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Mucopolissacaridose II
/
Iduronato Sulfatase
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article